PD-L1 (CPS) >= 10

About

Biomarker Type: Protein expression

Present: True

Marker: PD-L1

Unit: Combined Positive Score (CPS)

Equality: >=

Value: 10


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) HSE (2) PD-L1 (CPS) >= 10 Bladder Urothelial Carcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Pembrolizumab